



Figure e-2. Analysis of outcome in subtypes of GAD65-disease and NMDAR-AE (A)

Comparisons of the mRS-scores in GAD65-ab positive patients with different clinical phenotypes (encephalitis/ overlap syndrome, CA, and SPS) were performed at worst status (I) and at last follow-up (IV). Rituximab-treated patients as well as control patients were analysed.

(B) MRS-scores of patients with NMDAR-AE in the overall-cohort were compared in patients with or without tumor at worst status (I) and at last follow-up (IV).

The line represents the change in mRS scores dividing favourable mRS scores (0 - 2) and non-favourable mRS scores (≥ 3). Ordinal chi square test was applied to compare the distribution of the mRS-scores. GAD65, glutamic acid decarboxylase 65; mRS, modified Rankin Scale; NMDAR, N-Methyl-D-aspartate receptor.